Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC
NCT07116577
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
37
Enrollment
OTHER
Sponsor class
Conditions
mCRC
Interventions
RADIATION:
Palliative radiotherapy
DRUG:
Iparomlimab and tuvonralimab
DRUG:
TAS-102
DRUG:
Bevacizumab
Sponsor
Jinan Central Hospital